GenScript Biotechnology released its 2020 annual results, the non-cellular therapy business achieved the fastest growth rate in 5 years, and the net profit increased by more than 100%

March 29, 2021, global biotechnology company GenScript's bio (stock code: 01548.

During the performance period, the group's revenue was approximately US$390 million, an increase of 42.

Dr.

The non-cellular therapy business achieved the fastest growth rate in 5 years, and the net profit growth rate exceeded 100%

GenScript Group’s non-cellular therapy business performed well in 2020, with revenue increasing by 45.

Among them, the growth of life science services and products business will accelerate significantly in 2020.

At the same time, the life sciences business continues to explore technological innovations, laying the foundation for entering the high-growth market.

The biologics CDMO business will be upgraded to the "GenScript ProBio/GenScript ProBio" brand in 2020, and its revenue will increase by 78% in 2020 to reach US$40.

At the same time, relying on high-quality standards and years of global business development team layout, Boom Bio has strong revenue growth in domestic and overseas markets.

In 2020, the industrial synthetic biology product business, BSIQ, will continue to maintain a growth rate that exceeds the industry average and its main competitors, achieving a rapid growth of 24% in the industry, and currently ranks among the top three in the domestic industrial enzyme field.

In terms of innovation and research and development, Besjet continues to invest in iterative upgrades of key products, and at the same time constantly introduces the old to bring forth the new, helping customers solve new problems and pain points.

The cell therapy business continues to increase R&D investment and has gradually entered the commercial harvest period

Legend Bio, a subsidiary of the cell therapy business, has made continuous progress in 2020 and achieved multiple important milestones.

In December 2020, Legend Biotech formally submitted the marketing application (BLA) of Cidacchi Oriente (cilta-cel) to the US FDA.

It is reported that Legend Bio is expected to submit a European Marketing Authorization Application (MAA) for cilta-cel to the European Medicines Agency (EMA) in the first half of 2021, and is expected to submit a BLA to the National Medical Products Administration (NMPA) in the second half of 2021.

In addition to Cidac Oronza products, Legendary Bio's innovative product pipeline has been further expanded, and it is striding forward to become a platform-based CAR-T company.

Launched the world's first COVID-19 neutralizing antibody detection kit to help the development of new drugs and vaccines related to COVID-19

In 2020, the epidemic will have a profound impact on the entire human society, especially in the field of life sciences and health.

While fulfilling its social responsibilities, GenScript also relies on its platform and technical advantages to obtain good performance returns.

In May 2020, GenScript and Duke-National University of Singapore Medical School jointly launched the world's first kit that can quickly and effectively detect functional neutralizing antibodies, cPass? sVNT Kit, GenScript is exclusively responsible for the commercialization of its global market.
cPass? It is currently the only US FDA Emergency Use Authorization of the use of serological tests used to detect the infection through or being infected with SARS-CoV-2 individual kits and antibodies.
In addition, the kit has also passed European CE certification, Singapore HAS temporary authorization, Brazil ANVISA certification, Argentina ANMAT certification, and recently obtained a medical device license from the UAE Ministry of Health and Prevention (MOHAP).
Currently, it is also applying for approval in China.

It is reported that in February 2021, GenScript has reached a cooperation agreement with Nine Strong Biotech and Sinopharm Investment (a member company of Sinopharm Group) on the promotion of its commercial application in China, in order to better utilize the advantages of all parties and make this efficient Testing services will be promoted to the front line as soon as possible, benefiting more people, and contributing to China's anti-epidemic cause.

This joint cooperation with academia once again proves that GenScript has the powerful ability to cooperate extensively with global academic leaders and quickly transform scientific research results into commercial products.
In 2021, as the product channel gradually spreads and is licensed in more countries, the product is expected to contribute considerable sales.

Continue to invest in the core capabilities of the company and accumulate explosive power in steady development

In 2020, GenScript’s four business segments will steadily advance along the existing strategic layout, and continue to accumulate potential energy through continuous investment in core capabilities such as talent reserves, innovative research and development, and hardware facilities, so as to pay for the future of the company.
Sirui continues to invest in innovation and R&D to lay the foundation for future growth.
R&D expenses in 2020 will be 260 million US dollars, an increase of 41.
6% year-on-year.
Among them, the R&D expenses of the acellular therapy business unit have steadily maintained at about 10% of revenue.

In 2020, GenScript’s expenditure on capital expenditures is approximately US$130 million.
Including GMP facilities used to establish cell therapy business to support current clinical trials and future commercial needs, GMP facilities used in Nanjing and Zhenjiang to support the long-term development of CDMO business, and continuous product upgrades and facilities for life science services and product business segments Automated transformation to strengthen its business competitiveness and segment profitability.

In June, the life science building project, an integrated platform project of GenScript's innovative biopharmaceutical R&D and production services, covering more than 30,000 square meters, officially started in Zhenjiang, Jiangsu.
After being put into production, it will become GenScript’s customized peptide service production and R&D platform and an oligonucleotide production platform from research level to GMP production level, helping GenScript maintain the industry’s leading position in peptide drugs and oligonucleotide services.
Advantage.

At the same time, with the vigorous development and approval of antibody drugs and GCT drugs, Boom Bio will continue to invest in the ability to meet customer needs and support future growth.
In November, the antibody GMP production center in Nanjing was officially put into production, and the GMP production capacity of Boom Bio was increased to 2600L, which can provide clinical phase I and clinical phase II GMP production services.
At the same time, a second GMP-level plasmid factory is under construction in Zhenjiang, and is expected to be put into operation in the second half of 2021.
By then, the production capacity of plasmids and viruses will double; a third GMP facility to provide services for clinical and commercial GCT projects is also being planned.
among.

Dr.
Liu Zhenyu, Rotating Chief Executive Officer of GenScript, said, “In 2020, the new crown epidemic has brought challenges and opportunities to the life and health industry.
With the joint efforts of all GenScript people, the group is in the epidemic environment.
We have achieved excellent performance in the future.
In the future, we will continue to work hard to continuously create higher value for customers and shareholders, fulfill the group mission of using biotechnology to make people and nature healthier, and contribute to the development of the biotechnology industry and the cause of human health.
Keep fighting.